Abstract
In an evaluation of 213 patients from 15 kindreds with familial medullary thyroid carcinoma (MTC), we detected 41 subjects from two kindreds (L and O) who had MTC but no extra-thyroidal manifestations (hyperparathyroidism, phaeochromocytomas or mucosal neuromas) of multiple endocrine neoplasia (MEN) type 11a or 11b. In screening 178 members of the L and O kindreds, we found no evidence that any of them had died from MTC. To assess whether the malignancy was relatively indolent in these families, 20 selected subjects from the two kindreds were compared with 33 MEN IIa subjects. Both groups had clinically occult disease which was diagnosed biochemically by documenting elevated plasma calcitonin (CT) levels following stimulation with intravenous calcium and pentagastrin. There were no differences in the peak stimulated plasma CT levels at the time of diagnosis (1055 ± 236 pg/ml versus 1096 ± 191 pg/ml) or the incidence of regional lymph node metastases (0/20 versus 1/33) in the two groups. The mean age at diagnosis, however, was significantly higher in patients of the L and O kindreds than in patients with MEN 11a (43·1 ± 3·4 years versus 21·1 ± 2·2 years; P < 0·001) indicating that in the two kindreds the MTC either developed at a later age or grew more slowly. This study demonstrates that MTC may occur in a familial pattern distinct from its presentation as MEN IIa or MEN IIb. In this setting it appears to be the least aggressive form of MTC yet described.
Keywords: Thyroid cancers, familial medullary thyroid carcinoma, multiple endocrine neoplasia
Contributor Information
J R Farndon, University of Newcastle upon Tyne, UK.
G S Leightt, The Duke University Medical Center, Durham, North Carolina, USA.
W G Dilley, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
S B Baylin, The Oncology Center and Department of Medicine, The Johns Hopkins University Medical Institutions, Washington, DC, USA.
R C Smallridge, The Walter Reed Army Medical Center, Washington, DC, USA.
T S Harrison, The Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
S A Wells, Jr, University of Newcastle upon Tyne, UK.
References
- 1. Hazard JB, Hawk WA, Crile GJr. Medullary (solid) carcinoma of the thyroid - a clinicopathologic entity. J Clin Endocr 1959; 19: 152. [DOI] [PubMed] [Google Scholar]
- 2. Block MA, Horn RC, Miller JM, Barrett JM, Brush BE. Medullary carcinoma of the thyroid. Ann Surg 1967; 166: 403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Jackson CE, Tashjian AHJr, Block MA. Detection of medullary thyroid cancer by calcitonin assay in families. Ann Int Med 1973; 78: 845. [DOI] [PubMed] [Google Scholar]
- 4. Block MA, Jackson CE, Greenwald KA, Yott JB, Tashjian AHJr. Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Arch Surg 1980; 115: 142. [DOI] [PubMed] [Google Scholar]
- 5. Wells SAJr, Baylin SB, Gann DS, Farrell RE, Dilley WG, Preissig SH, Linehan WM, Cooper CW. Medullary thyroid carcinoma: relationship of method of diagnosis to pathologic staging. Ann Surg 1978; 188: 377. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Wells SAJr, Baylin SB, Linehan WM, Farrell RE, Cox EB, Cooper CW. Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg 1978; 188: 139. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Hennessey JF, Wells SAJr, Ontjes DA, Cooper CW. A comparison of pentagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid. J Clin Endocrin Metab 1974; 39: 487. [DOI] [PubMed] [Google Scholar]
- 8. Baylin SB, Hsu TH, Stevens SA, Kallman CH, Trump DL, Beavan MA. The effects of L-dopa on in vitro and in vivo calcitonin release from medullary thyroid carcinoma. J Clin Endo Metab 1979; 48: 408. [DOI] [PubMed] [Google Scholar]
- 9. Wells SAJr, Farndon JR, Dale JK, Leight GS, Dilley WG. Long-term evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and heterotopic autotransplantation. Ann Surg 1980; 192: 451. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Cohen G, Goldenberg M. The simultaneous fluorimetric determination of adrenaline and non-adrenaline in plasma. J Neurochem 1957; 2: 58. [DOI] [PubMed] [Google Scholar]
- 11. Pisano JJ, Crout JR, Abraham D. Determination of 3-methoxy-4-hydroxymandelic acid in urine. Clin Chem Acta 1962; 7: 285. [DOI] [PubMed] [Google Scholar]
- 12. Pisano JJ. In: Rall JE, Kopin IJ (eds), Methods in Investigative and Diagnostic Endocrinology, Vol I. American Elsevier, New York: 1972: 474. [Google Scholar]
- 13. Baylin SB. Medullary carcinoma of the thyroid gland: use of biochemical parameters in detection and surgical management of the tumour. Surg Clin North Am 1974; 54: 309. [DOI] [PubMed] [Google Scholar]
- 14. Chong GC, Beahrs OH, Sizemore GW, Woolner LH. Medullary carcinoma of the thyroid gland. Cancer 1975; 35: 695. [DOI] [PubMed] [Google Scholar]